pharmaphorum

AUGUST 6, 2021

There was a dramatic increase in the launch of health-related mobile applications last year, taking the total number on offer in app stories to 350,000 – and while average quality is currently “middling” it is on the rise, according to a report from IQVIA. The pandemic contributed to another 90,000 apps being introduced in 2020 – an average of 250 per day – and this coupled with rising number and functionality of wearable devices “provides evidence of digital health’s acc

145

145

Outsourcing Pharma

AUGUST 5, 2021

A leader from the clinical research tech specialist explains how the use of AI is increasing in the field and outlines the many ways it could SOMETHING.

145

145

Fierce Healthcare

AUGUST 4, 2021

U.S. ranks last among 10 other countries in new study on healthcare systems. agliadkovskaya. Wed, 08/04/2021 - 10:27.

145

145

Pharma Times

AUGUST 4, 2021

Sativex is a complex botanical formulation that contains the principal cannabinoids THC and CBD

64

64

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

pharmaphorum

AUGUST 4, 2021

Spinal Muscular Atrophy (SMA) is a rare disease affecting the motor nerve cells in the spinal cord. It’s a debilitating condition that affects 1 per 8,000 to 10,000 people worldwide , impacting their ability to walk, eat, and breathe. SMA Type 1 represents an estimated 50% of all cases, for which life expectancy is less than 18 months without treatment. .

Patient Care 145

Patient Care FDA 145

Outsourcing Pharma

AUGUST 3, 2021

A leader from the company says to ensure medicines keep reaching the patients that need them, the industry must revamp outdated technologies and techniques.

131

131

Pharma Times

AUGUST 5, 2021

Neutralising antibody titers were observed in 98.

Vaccines 56

Vaccines 56

pharmaphorum

AUGUST 5, 2021

Protein-protein interactions (PPIs) are becoming increasingly relevant in the pathology of many diseases, including cancer. The issue, however, is developing an effective way of targeting them. . The latest advancements in methods targeting PPIs are designed to overcome the challenges limiting the conventional methods. Targeting PPIs offers another potential therapeutic target for diseases with complex biological profiles.

Compounding 126

Compounding Chemotherapy 126

Outsourcing Pharma

AUGUST 3, 2021

The Psychae Institute, established by a global team of scientists, will conduct pre-clinical and clinical research around psychedelic medicine development.

130

130

Fierce Healthcare

AUGUST 5, 2021

Ascension Michigan to pay nearly $3 million in latest settlement to resolve fraud claims. agliadkovskaya. Thu, 08/05/2021 - 13:30.

111

111

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharma Times

AUGUST 2, 2021

Saphnelo is the first type I interferon receptor agonist to receive regulatory approval

54

54

pharmaphorum

AUGUST 4, 2021

Fresenius has launched a virtual reality based training programme for people undergoing home dialysis in Germany, its home market, ahead of a rollout in other countries later this year. The VR system – called stay•safe MyTraining VR – is designed for use in patients undergoing peritoneal dialysis, which uses the peritoneum in a person’s abdomen as the membrane through which fluid and dissolved substances are exchanged with the blood.

111

111

Outsourcing Pharma

AUGUST 2, 2021

According to the neurodegenerative-disease-focused biotechnology firm, their research could bring hope to patients with amyotrophic lateral sclerosis.

119

119

PDS Blog

AUGUST 2, 2021

As an independent pharmacy, your goal is to become a healthcare destination in your community. That means going far beyond dispensing. It means attracting patients that will stay with your pharmacy for the long-term. And don’t forget that a great number of referrals can come from physicians and other members of the community. Being involved […].

Independent Pharmacies 52

Independent Pharmacies 52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharma Times

AUGUST 5, 2021

Agreement will support use of the 'best evidence-based healthcare' in the NHS

52

52

pharmaphorum

AUGUST 4, 2021

Eli Lilly and Incyte have another rival in the rear-view mirror for Olumiant in alopecia areata after Pfizer reported that its ritlecitinib improved scalp hair regrowth in a late-stage trial. In the phase 2b/3 ALLEGRO trial, JAK inhibitor ritlecitinib hit its primary objective of improving the area of scalp covered by hair in people with this autoimmune form of hair loss, giving Pfizer a positive readout in the first of two trials that will form the basis of regulatory filings for the drug.

Labelling 107

Labelling FDA Immunization 107

Outsourcing Pharma

AUGUST 3, 2021

The success of mRNA vaccine technology could be one of the new opportunities for US pharmaceutical manufacturing looking forward, with pandemic investments helping turbocharge the sector.

Vaccines 110

Vaccines 110

Pharma Marketing Network

AUGUST 2, 2021

EHSx can connect your brand with your target audiences on over 4,000 quality whitelist healthcare publishers, and 10,000 pharma-safe, non-endemic properties. Download our EHSX one-pager to learn more! Name *. First. Last. Email *. Title Company Hidden Lead Source * Web Active Prospecting Sales Ad-Label Advertising - Offline Advertising - Online Advertising - Online - FocalPoint Advertising - Online - Mobile Advertising - Online - TrendMD Conference/Trade Show Date Connected on LinkedIn Domains D

Labelling 52

Labelling 52

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharma Times

AUGUST 4, 2021

Less than one in 20 children had symptoms for more than four weeks

52

52

pharmaphorum

AUGUST 6, 2021

Moderna made a massive $4.2 billion from sales of just under 200 million doses of its COVID-19 vaccine, taking its tally since approval to around $6 billion from 302 million shots. The tally makes the SpikeVax (mRNA-1273) vaccine the second biggest seller behind Pfizer/BioNTech’s Comirnaty, which pulled in $7.8 billion in the second quarter and $11.3 billion since the start of the year.

Vaccines 105

Vaccines Immunization 105

Outsourcing Pharma

AUGUST 4, 2021

An industry study from the producer of CPhI North America shows the pandemic and other factors are contributing to a very dynamic pharmaceutical market.

105

105

The Infectious Pharmacist

AUGUST 1, 2021

Photo by Jeff Stapleton on Pexels.com. I feel a bit like Michael Corleone in Godfather Part 3 (yes, it’s the worst of the three, but it’s good for this line): Just when I thought I was out they pull me back in! Unfortunately the only messages about masks, vaccines, and COVID-19 that we’re hearing are: Just when you thought it was safe to go back in the water.

Vaccines 52

Vaccines Documentation Hospitals Communication 52

Pharma Times

AUGUST 4, 2021

Phase III trials did not demonstrate sufficient clinical benefit.

52

52

pharmaphorum

AUGUST 6, 2021

Patient enrollment is a common issue across many therapeutic areas in clinical research. Psychiatric disorders in particular represent a trial area with significantly high drop-out rates and poor patient recruitment. The reasons behind this problem, however, are rarely studied or understood. Despite this, new strategies devised over the last five years are beginning to reverse the trend, and both reduce stigma and increase awareness to funnel new patients into these important trials. .

Hospitals 105

Hospitals Communication 105

Outsourcing Pharma

AUGUST 2, 2021

Arcturus Therapeutics and its Vietnam partner Vinbiocare will take ARCT-154, a next-generation Arcturus vaccine targeting SARS-CoV-2 variants of concern, into a Phase 1/2/3 trial. The companies will also establish a vaccine manufacturing centre in Vietnam.

Vaccines 105

Vaccines 105

Med Ed 101

AUGUST 4, 2021

Excess calcium levels can be life-threatening if they become severely elevated (>14 mg/dL), causing symptoms such as polyuria and polydipsia due to nephrogenic diabetes insipidus, nephrolithiasis, bone pain, nausea, vomiting, anorexia, confusion, rare cardiac arrhythmias, and coma. Calcium homeostasis in the body is dependent upon parathyroid hormone (PTH), vitamin D, calcitonin (to a lesser extent), […].

40

40

Pharma Times

AUGUST 3, 2021

The study will be the largest clinical trial of its kind in the UK, involving over 600 pregnant women

Vaccines 52

Vaccines 52

pharmaphorum

AUGUST 3, 2021

The FDA has relaxed a clinical hold on clinical trials of Novartis’ intrathecal formulation of spinal muscular atrophy (SMA) gene therapy Zolgensma, allowing a new phase 3 trial to get underway. Zolgensma (onasemnogene abeparvovec) is already approved as an intravenous treatment in babies and very young children for the rare muscle-wasting disease, but the new OAV-101 IT version is designed to unlock use of the drug in older SMA patients.

FDA 105

FDA 105

Outsourcing Pharma

AUGUST 2, 2021

The drug, intended for adult patients with moderate-to-severe systemic lupus erythematosus, is the only new therapy approved for SLE in more than a decade.

FDA 98

FDA 98

Med Ed 101

AUGUST 1, 2021

In this article, I wanted to share information on tapering clonidine. This drug can cause serious rebound hypertension when abruptly discontinued and patients may not understand or realize that this risk exists. Here’s a case scenario that demonstrates tapering clonidine. JS is a 52-year-old female who has a history of resistant hypertension. She was doing […].

40

40

Pharma Times

AUGUST 6, 2021

The finalists have been confirmed for the 2021 Clinical Researcher of the Year – The Americas competition.

49

49

pharmaphorum

AUGUST 2, 2021

Ipsen’s new chief executive David Loew pledged to ramp up spending on the company’s pipeline when he took the helm last year, and a flurry of licensing deals in the last few weeks shows that push is starting to gather momentum. The French company – which focusing on cancer, neuroscience and rare diseases – has just snapped up two programmes from US biotech Exicure that span the latter two areas, targeted at rare neurodegenerative disorders Huntington’s disease and Angelman synd

105

105

Outsourcing Pharma

AUGUST 3, 2021

Adoption of single-use technologies has grown exponentially over the last decade: but what will drive the tech forward in the coming years?

98

98